<i>Saccharomyces cerevisiae</i>Laryngitis and Oral Lesions in a Patient with Laryngeal Carcinoma

Algazaq, Jumanah; Akrami, Kevan; Martínez, Fernando D.; McCutchan, Allen; Bharti, Ajay

doi:10.1155/2017/2941527

Cited by 8 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A series of recent study suggested that S. cerevisiae should be considered as a potential opportunistic pathogen especially for patients with immunosuppression, cancer and other critical illnesses [44]. One of the latest studies demonstrated that the abundance S. cerevisiae in the guts of COVID-19 patients with fever were significantly higher than in COVID-19 patients with non-fever supporting our present results [47].…”

Section: Despite Hundreds Of Thousands Of Fungal Species Only a Few C...supporting

confidence: 89%

“…On the other hand, S. pastorianus is a recently evolved interspecies hybrid of Saccharomyces genus commonly used in the brewing industry. Different species of Saccharomyces are recognised as beneficial probiotics that can help humans with IBS, Crohn’s disease, diarrhoea, and a range of gastrointestinal infections [44, 45]. The co-evolution of humans and fungi suggests that complex mechanisms exist to allow the host immune system to respond to fungi [46].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Metagenomic analysis reveals the abundance and diversity of opportunistic fungal pathogens in the nasopharyngeal tract of COVID-19 patients

Hoque

Rahman²,

Sarkar

et al. 2022

Preprint

View full text Add to dashboard Cite

The nasopharyngeal tract (NT) of human is a habitat of a diverse microbial community that work together with other gut microbes to maintain the host immunity. In our previous study, we reported that SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiome (bacteria, archaea and commensal respiratory viruses) but increases the abundance of pathobionts. This study aimed to assess the possible changes in the resident fungal diversity by the inclusion of opportunistic fungi due to the infection of SARS-CoV-2 in the NT of humans. Twenty-two (n = 22) nasopharyngeal swab samples (including COVID-19 = 8, Recovered = 7, and Healthy = 7) were collected for RNAseq-based metagenomics analyses. Our results indicate that SARS-CoV-2 infection significantly increased (p < 0.05, Wilcoxon test) the population and diversity of NT fungi with a high inclusion of opportunistic pathogens. We detected 863 fungal species including 533, 445, and 188 species in COVID-19, Recovered, and Healthy individuals, respectively that indicate a distinct microbiome dysbiosis due to the SARS-CoV-2 infection. Remarkably, 37% of the fungal species were exclusively associated with SARS-CoV-2 infection, where Saccharomyces cerevisiae (88.62%) and Phaffia rhodozyma (10.30%) were two top abundant species in the NT of COVID-19 patients. Importantly, 16% commensal fungal species found in the Healthy control were not detected in either COVID-19 patients or when they were recovered from the COVID-19. Pairwise Spearman's correlation test showed that several altered metabolic pathways had significant positive correlations (r > 0.5, p < 0.01) with dominant fungal species detected in three metagenomes. Taken together, our results indicate that SARS-CoV-2 infection causes significant dysbiosis of fungal microbiome and alters some metabolic pathways and expression of genes in the NT of human. Findings of our study might be helpful for developing microbiome-based diagnostics, and also devising appropriate therapeutic regimens including antifungal drugs for prevention and control of concurrent fungal coinfections in COVID-19 patients.

show abstract

Section: Despite Hundreds Of Thousands Of Fungal Species Only a Few C...supporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Metagenomic analysis reveals the abundance and diversity of opportunistic fungal pathogens in the nasopharyngeal tract of COVID-19 patients

Hoque

Rahman²,

Sarkar

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…Although S. cerevisiae is not a typical human pathogen, the emergence of opportunistic S. cerevisiae infections has been reported in patients with chronic disease, cancer, and immunosuppression [ 51 ]. Moreover, considerable insights into RCD have been gained through studies using this organism as a model.…”

Section: Regulated Cell Death In Fungimentioning

confidence: 99%

Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics

Yeaman

Büttner

Thevissen

2018

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

The rise of microbial pathogens refractory to conventional antibiotics represents one of the most urgent and global public health concerns for the 21st century. Emergence of Candida auris isolates and the persistence of invasive mold infections that resist existing treatment and cause severe illness has underscored the threat of drug-resistant fungal infections. To meet these growing challenges, mechanistically novel agents and strategies are needed that surpass the conventional fungistatic or fungicidal drug actions. Host defense peptides have long been misunderstood as indiscriminant membrane detergents. However, evidence gathered over the past decade clearly points to their sophisticated and selective mechanisms of action, including exploiting regulated cell death pathways of their target pathogens. Such peptides perturb transmembrane potential and mitochondrial energetics, inducing phosphatidylserine accessibility and metacaspase activation in fungi. These mechanisms are often multimodal, affording target pathogens fewer resistance options as compared to traditional small molecule drugs. Here, recent advances in the field are examined regarding regulated cell death subroutines as potential therapeutic targets for innovative anti-infective peptides against pathogenic fungi. Furthering knowledge of protective host defense peptide interactions with target pathogens is key to advancing and applying novel prophylactic and therapeutic countermeasures to fungal resistance and pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 99%

“…On the other hand, S. pastorianus is a recently evolved interspecies hybrid of Saccharomyces genus commonly used in the brewing industry. Different species of Saccharomyces are recognised as beneficial probiotics that can help humans with IBS, Crohn's disease, diarrhoea, and a range of gastrointestinal infections [54,55]. The co-evolution of humans and fungi suggests that complex mechanisms exist to allow the host immune system to respond to fungi [56].…”

Section: Plos Onementioning

confidence: 99%

Transcriptome analysis reveals increased abundance and diversity of opportunistic fungal pathogens in nasopharyngeal tract of COVID-19 patients

Hoque

Rahman²,

Sarkar

et al. 2023

PLoS ONE

View full text Add to dashboard Cite

We previously reported that SARS-CoV-2 infection reduces human nasopharyngeal commensal microbiomes (bacteria, archaea and commensal respiratory viruses) with inclusion of pathobionts. This study aimed to assess the possible changes in the abundance and diversity of resident mycobiome in the nasopharyngeal tract (NT) of humans due to SARS-CoV-2 infections. Twenty-two (n = 22) nasopharyngeal swab samples (including COVID-19 = 8, Recovered = 7, and Healthy = 7) were collected for RNA-sequencing followed by taxonomic profiling of mycobiome. Our analyses indicate that SARS-CoV-2 infection significantly increased (p < 0.05, Wilcoxon test) the population and diversity of fungi in the NT with inclusion of a high proportion of opportunistic pathogens. We detected 863 fungal species including 533, 445, and 188 species in COVID-19, Recovered, and Healthy individuals, respectively that indicate a distinct mycobiome dysbiosis due to the SARS-CoV-2 infection. Remarkably, 37% of the fungal species were exclusively associated with SARS-CoV-2 infection, where S. cerevisiae (88.62%) and Phaffia rhodozyma (10.30%) were two top abundant species. Likewise, Recovered humans NT samples were predominated by Aspergillus penicillioides (36.64%), A. keveii (23.36%), A. oryzae (10.05%) and A. pseudoglaucus (4.42%). Conversely, Nannochloropsis oceanica (47.93%), Saccharomyces pastorianus (34.42%), and S. cerevisiae (2.80%) were the top abundant fungal species in Healthy controls nasal swabs. Importantly, 16% commensal fungal species found in the Healthy controls were not detected in either COVID-19 patients or when they were cured from COVID-19 (Recovered). We also detected several altered metabolic pathways correlated with the dysbiosis of fungal mycobiota in COVID-19 patients. Our results suggest that SARS-CoV-2 infection causes significant dysbiosis of mycobiome and related metabolic functions possibly play a determining role in the progression of SARS-CoV-2 pathogenesis. These findings might be helpful for developing mycobiome-based diagnostics, and also devising appropriate therapeutic regimens including antifungal drugs for prevention and control of concurrent fungal coinfections in COVID-19 patients.

show abstract

Saccharomyces cerevisiaeLaryngitis and Oral Lesions in a Patient with Laryngeal Carcinoma

Cited by 8 publications

References 15 publications

Metagenomic analysis reveals the abundance and diversity of opportunistic fungal pathogens in the nasopharyngeal tract of COVID-19 patients

Metagenomic analysis reveals the abundance and diversity of opportunistic fungal pathogens in the nasopharyngeal tract of COVID-19 patients

Regulated Cell Death as a Therapeutic Target for Novel Antifungal Peptides and Biologics

Transcriptome analysis reveals increased abundance and diversity of opportunistic fungal pathogens in nasopharyngeal tract of COVID-19 patients

Contact Info

Product

Resources

About